| Market Capitalization (Millions $) |
46 |
| Shares
Outstanding (Millions) |
115 |
| Employees |
20 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-100 |
| Cash Flow (TTM) (Millions $) |
20 |
| Capital Exp. (TTM) (Millions $) |
0 |
Allovir Inc
Allovir Inc is a biotechnology company that specializes in the development of T-cell immunotherapies for the treatment of viral diseases and cancer. The company's main focus is on developing allogeneic, off-the-shelf T-cell therapies that can be used to target and destroy viruses or cancer cells in patients. Allovir's approach involves genetically modifying T-cells to express specific receptors that recognize and attack infected or malignant cells, providing a targeted and potent therapeutic approach. The company aims to address critical unmet needs in patients with life-threatening viral infections or cancer who may not be eligible for other treatment options.
Company Address: PO Box 44, 1661 Massachusetts Avenue Lexington 2420 MA
Company Phone Number: 433-2605 Stock Exchange / Ticker: NASDAQ ALVR
|
1.25%